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Abstract
The human gut hosts a microbial community which actively contributes to the host metabolism and has thus remarkable
effect on our health. Intestinal microbiota is known to interact remarkably with the dietary constituents entering the colon,
causing major metabolic conversions prior to absorption. To investigate the effect of microbial metabolism on the
phytochemical pool of rye bran, we applied an in vitro simulated colonic fermentation where samples were collected with
intervals and analyzed by LC-MS based non-targeted metabolite profiling. The analyses revealed extensive metabolic
turnover on the phytochemical composition of the bran samples, and showed effects on all the metabolite classes detected.
Furthermore, the majority of the metabolites, both the precursors and the conversion products, remained unidentified
indicating that there are numerous yet unknown phytochemicals, which can potentially affect on our health. This underlines
the importance of comprehensive profiling assays and subsequent detailed molecular investigations in order to clarify the
effect of microbiota on phytochemicals present in our everyday diet.
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Introduction
Humans have co-evolved with their symbiotic gut bacteria
(microbiota) that are metabolically active organisms influencing
host metabolism and hence health [1–3]. It is well established that
human metabolic processes are encoded not only by the genome,
but also contributed by the genetic information in microbiota
resulting in transgenomic metabolism with two way crosstalk:
microbiota contributing to human metabolism, physiology and
gene expression, which in turn modulate microbiota. The
composition of microbiota is reflected by the lifestyle, diet and
genetics of the host and thus varies extensively [4,5]. Correlations
between specific range of microbiota have been implicated to e.g.
susceptibility to obesity [6,7], and predisposition to diseases like
cancer and bowel diseases [8,9]. A major metabolic impact of
microbiota is on the dietary constituents, which are not absorbed
in the upper intestinal tract, but are subjected to metabolism by
microbiota in the colon, and thereafter enter the circulation. The
microbial conversion of plant-food components involves fermen-
tation of indigestible carbohydrates to short-chain fatty acids,
providing additional energy from non-digestible intake [10].
Additionally, the microbial metabolism causes major structural
transformations on the dietary phytochemicals such as the
polyphenols [11–13].
In vitro colonic models have allowed the detailed analysis of
metabolic activities of microbiota on specific metabolites or
metabolite groups of dietary products. The in vitro models enable
to follow the temporal metabolism of the phytochemicals by
microbiota (which metabolites disappear and which emerge),
whereas analysis of feces only shows the remaining metabolites
that have not been absorbed, and analysis of blood or urine
samples shows the absorbed metabolites that have undergone host
metabolic functions. The majority of the studies in the in vitro
colonic model have focused on specific metabolites or metabolite
groups [14–18]. The dietary phytochemicals that have been
studied in most detail are the polyphenols. Typical metabolic
events include cleavage of the ester or glycosidic bond, reduction
of double bonds, dehydroxylation, demethylation, decarboxyl-
ation, and ring-fission, and it is concluded that relatively small
number of phenolic end products, mostly benzoic-, phenylacetic-,
phenylpropionic and phenylvaleric acids with different degrees of
hydroxylation are formed from relatively diverse group of phenolic
metabolites [11].
During the past few years, large-scale metabolomics analyses by
various techniques have provided new insights to the microbial
activities allowing the comprehensive and concomitant character-
ization of multiple metabolite profiles. However, it has so far been
mainly applied to samples of mammalian origin in various set-ups
[19–22]. In this analysis we show the effect of colonic microbiota
in vitro on the semi-polar metabolite pool of rye bran fractions as
examined by the non-targeted LC-MS metabolite profiling. The
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iate tools for general data visualization, as well as univariate
comparison to demonstrate the most significant metabolite
markers reflecting the metabolic shift in each of the fractions.
The analysis showed the extensive impact of microbiota on the rye
phytochemicals, as far majority of the metabolite signals observed
in the samples taken at consecutive time points of the fermentation
(0, 4, 12 and 48 hours) had alterations in the intensity, and only
fraction of those metabolites are such that are previously known to
exist in rye.
Results and Discussion
General Evaluation of the Impact of the Microbial
Treatment on the Rye Phytochemical Pools
In our analysis two different fractions of rye bran were subjected
to the in vitro colon model mimicking caecal conditions. The rye
bran fractions were prepared from extruded rye bran as described
earlier [23]. The extractable fraction (E) contained chromato-
graphically purified soluble phytochemicals and the unextractable
fraction (UE) resilient against enzymatic hydrolysis contained the
residual matrix with bound phytochemicals. Because the E
fraction was earlier observed to have low pH in the process
interfering the metabolite conversions, it was applied also at a
lower dose (EL) allowing more physiological pH (above 5.5) and
enabling the metabolite conversions [23]. All the incubated
fractions were analysed by UPLC-qTOF-MS metabolite profiling
and subsequent data evaluation.
PCA demonstrates the metabolite shift during the in vitro
fermentation. The in vitro simulated colonic fermentation
caused extensive metabolic turnover in all the rye bran prepara-
tions studied. The effect is visible already from the total ion
chromatograms of different samples and time points (Figure S1,
Figure S2, Figure S3, Figure S4). Detailed examination of the
metabolite signals was started by cleaning the data set from low-
significance and erroneous markers resulting in set of 2147
metabolite markers. The principal component analysis (PCA) [24]
brought out clear differences between sample group metabolomes
as shown for the PCs 1 and 2 (Figure 1). The alterations were
extensive enough to be visualized in the non-supervised manner,
and there was no need to use more powerful approaches like PLS-
DA [25]. First two principal components depict the differences of
metabolite profiles between E(L), UE and FB samples, and show
also the drift in metabolite content between the different time
points. The EL samples show larger change than the E samples,
indicating that the conversion process at the two different
concentrations of the extractable fraction had quantitative
differences (Figure 1). The larger impact of the fermentation on
the EL fraction most likely resulted from the pH conditions
resembling the in vivo conditions more closely than the E sample.
Similarly as for the EL samples, also in the resilient UE fractions
the pH remained favorable for the microbial conversion, and the
metabolic shift is clearly visible in PCA (Figure 1).
Interestingly, metabolic changes were observed also in the faecal
background samples, most likely originating from the diets of the
donors of the faecal inoculum comprising of remaining dietary
chemicals and their non-absorbed metabolites. The donors were
prevented from eating rye, flaxseed or berries, but several plant
foods, especially fruits, berries, vegetables, seeds and cereals, share
common phenolic acid and lignan metabolites. Moreover, various
phenolic precursors result to the same end products in the
conversion by the microbiota, like phenyl propionic acid that was
clearly produced in the faecal background samples [11].
Cluster Analysis Groups Metabolite Markers with
different Accumulation Patterns
The cleaned marker set was next analyzed by the K-means
cluster analysis in order to examine the kinetics of the different
metabolite signals throughout the three fermentations. K-means
clustering sorts the data by comparing each of the markers against
each other, and grouping them with their nearest mean. In our
data, the metabolite signals were grouped based on their presence
in the different rye bran samples, their time profile (early,
transient, late appearance) and strength of the metabolite signal
(Figure 2). The classification of markers to a narrow set of clusters
representing metabolites behaving similarly in the different sample
types throughout the incubation is a valuable asset for the
identification of the metabolites in a non-targeted metabolite
profiling assay.
Cluster 1 contained the metabolites that are present in the
samples at the onset of the fermentation, thus representing the
substrates for the microbial conversions. This applies to all the
three different samples (E, ELand UE) (Figure 2). All the remaining
clusters represent metabolites that accumulate during the in vitro
incubation, but differ in their proportional amounts between the
different samples. It is notable that no such clear group was formed
that would contain compounds that are uniquely formed in the UE
samples and would not be found in the extractable fraction at all,
suggesting that the differences in the phytochemical pool between
the extractable and unextractable fractions are mainly quantitative,
not so much qualitative.
Clusters 5 and 8 represent metabolites that are produced in all
the three sample types, showing a clear increase after four hours of
incubation. Many of these markers emerge also in the faecal
background samples, indicating metabolites originating from the
diet of the donors for the inoculums. Cluster 6 is formed from
metabolites that are most clearly detected in the EL-samples,
representing a trend line emerging strikingly in the 4 h samples,
and slightly diminishing after 12 hours. Many of the metabolites in
cluster 6 came out also in the incubation of the unextractable
fraction. Similarly, markers in cluster 7 were those that accumu-
lated initially and diminished in the incubation of the EL-fraction.
These two clusters (i.e. 6 and 7) thus represented intermediate
products of the bacterial incubation of the rye metabolites. Cluster
2 contained the markers that are highest at the end of the
fermentation in EL- and UE-fractions, showing the final end
products of the incubation. Notably, many of these metabolites are
formed readily in the fecal background samples, suggesting similar
metabolite profile from the diet of the donors. Cluster 9 is formed
from metabolites that are accumulating early in the incubation
(4 h.) in both the E and EL-samples, and then remain on relatively
constant level in both samples, in higher concentration in the E
than EL-fraction. Clusters 3 and 4 are the minority groups in this
analysis, cluster 3 showing a peculiar metabolite group being
present mostly in the E and UE fractions from 4 h. incubation
onwards, but not so much in the EL fraction. Cluster 4 represents
metabolites that remain in relatively constant level in all the
sample types including faecal background, and are likely
endogenous bacterial metabolites excreted during the incubation.
One such metabolite is clearly visible also in the base peak ion
chromatogram of all the sample types (m/z 319.19, Figure S1,
Figure S2, Figure S3, Figure S4).
Different Metabolite Families Exhibit Distinct Kinetics
during the in vitro Incubation
From each cluster, the metabolites that showed statistically
significant changes between two time points were selected for
LC-MS Metabolomics of Microbiota Treated Rye
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Detailed figures on the number of metabolite markers found in
each sample type are also provided in Figure S5. Only a small
fraction of the addressed metabolites were such that they could be
identified based on earlier reports of rye chemical composition,
this being the case for both the substrate phytochemicals as well as
the end products. This highlights the fact that in such non-targeted
assay when metabolite repertoire is analyzed in a comprehensive
manner, novel, potentially important metabolites that are not in
the scope of targeted measurements can be detected. The known
compounds that were detected in this study were mainly phenolic
compounds of rye or their metabolites, and the unidentified
compounds are presently being investigated with focused tech-
niques for identification.
The most abundant metabolite markers are shown together
with some of the most interesting unknown markers on a heat-map
graph (Figure 3). Further information on the identification
procedure (MS/MS fragmentation and references) is described
in Table S1. We observed major alteration in the compositions of
the phenolic acids (Figure 3). However, as the microbial
modification of phenolic acids is discussed to large extent
elsewhere [11,15,26], it is not addressed in detail here.
Lignan sub-classes were affected differentially by the
microbiota. Our earlier analysis on rye bran lignans revealed
several novel oligolignans, e.g. Buddlenol C, Buddlenol D and
Methoxyhedyotisol A [27]. All of these lignans were clearly
degraded in the bacterial fermentation, as their metabolite signals
were decreasing after 4 h of incubation, particularly in the EL
fraction in which they were reduced to trace levels (Figure 4).
These lignans were also detected in the UE-fraction prior to
incubation, and they likewise disappeared in the beginning of the
in vitro treatment. Also other resinol type-lignans containing the
furofuran double-ring structural moiety [28] appeared in the
samples with very similar accumulation profiles, e.g. syringaresinol
and hydroxysyringaresinol (Figure 4). All these metabolites were
represented in cluster 1 in the K-means analysis. In addition, other
lignan types with different pattern of accumulation e.g. matair-
esinol and secoisolariciresinol were identified (Figure 4). On
contrary to the furofuran containing lignans, these were present at
low levels in the beginning of incubation, but showed a transient
peak after 4 h of incubation, and subsequently decreased again (in
all three sample types) (Figure 4). This suggests that the furofuran-
structured lignans are present as precursor lignans synthetized
in planta, and serving as substrates for the microbial conversion and
resulting in the other lignan-types. The different accumulation of
the different lignan types clearly refer to separate metabolic
processes most likely involving various different enzymatic
reactions, potentially by different microbial species.
It has been reported that syringaresinol is the most abundant
lignan in rye [29] but also other types of lignans are occurring in
rye naturally without microbiota conversion, suggesting that they
are also produced in planta, although smaller quantities than the
Figure 1. Principal component analysis, component 1 vs. component 2. The different sample types are depicted as follows: E, extractable
fraction; EL, extractable fraction in low concentration; UE, unextractable fraction; FB, fecal background.
doi:10.1371/journal.pone.0039322.g001
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accumulation in our analysis, matairesinol and secoisolariciresinol,
are most likely released from the matrix or converted from other
resinol-type lignans. Such metabolite conversions have been
detected in vitro [30]. The chromatographic region containing
the eluting lignans was extremely dense in metabolites as reported
also earlier [27] and it included additional yet unidentified lignan-
like metabolites displaying differential accumulation in the
different sample types.
Microbial metabolism of plant lignans to the mammalian
lignans enterodiol and enterolactone is one of the most studied
microbial conversion process of dietary constituents [30–33]. In
our analysis both of these enterolignans were detected, but in
significantly smaller signals than the lignans. Enterodiol accumu-
lated to the highest level at the EL and UE fractions at the latter
stage of the incubation (24–48 hours; Figure 4), and enterolactone
was detected mostly at the end of incubation in the UE samples,
but also extensively in the faecal background samples. The ratio of
enterolactone- and enterodiol-producing bacteria is 1:2000
indicating that enterodiol-synthesizing bacteria are dominant
while enterolactone-forming microbiota is a minor population
[34]. In our case mainly the formation of enterodiol was observed
in the EL and UE fractions, and enterolactone mostly only at the
end of UE and FB incubation, which observations are in
accordance with earlier targeted measurements of enterolignans
in in vitro model [23,33] as it appears that rigid structure in UE and
the removal acidic components in EL favours enterolactone
conversion. It is noteworthy to mention, however, that the strength
of the signals for the furofuran-type lignans in this analysis was by
far more intense than those for the enterodiol and enterolactone,
which refers that at least in our analytical conditions the
enterolignans are not produced from the plant liganas in 1:1
ratio, and that there might be other, yet non-characterized
conversion products of the lignans.
Benzoxazinoid aglycones are released by the
microbiota. Benzoxazinoids are relatively rare dietary phyto-
chemicals restricted to a narrow set of plant species including
rye, wheat and maize. Our earlier analyses showed that these
metabolites are present in rye bran as hexose and di-hexose
derivatives [35]. In the in vitro fermentation, the hexose
containing derivatives were rapidly deconjucated, as seen for
the two most abundant benzoxazinoids, DIBOA-hex and
HBOA-hex (Figure 3). In contrast, the released aglycone of
HBOA was visible as an intense signal after 4 h in both the E
and the EL fractions. Candidate markers for the aglycone of
DIBOA were detected as well; however, they could not be
Figure 2. K-means cluster analysis of the cleaned data set (2147 markers). The different sample types are depicted as follows: E, extractable
fraction; EL, extractable fraction in low concentration; UE, unextractable fraction; FB, fecal background, as three replicates in each sampling time (0, 4,
12, 48 h).
doi:10.1371/journal.pone.0039322.g002
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molecular weight. In the EL sample, the fermentation continued
further, as the amount of the free HBOA aglycone was reduced
in the 12 and 48 h samples (Figure 5). The microbial
degradation product of the benzoxazinones was not identified
in this study. In the same chromatographic region, we detected
several nitrogen- containing metabolites that were most abun-
dant at the end of the fermentation (e.g. m/z 150; Figure 4),
which could be either degradation products from the benzox-
azinoids, or potentially microbially processed amino acids.
Benzoxazinoids as dietary products have not yet gained much
attention. The end products for this metabolite group have not
been studied, and whether they can be absorbed to circulation
is not known. A very recent study, however, describes that in
pig feeding trial [36] benzoxazinoids are absorbed and
detectable in urine and blood postprandially, which suggests
that they may be bioavailable in humans as well.
Large amount of rye bran phytochemicals and their
microbial conversion products remain to be
identified. One of the largest groups represented in the cluster
analysis were metabolites that are degraded during the incubation
(see cluster 1; Figure 2). Based on earlier studies we were able to
identify many of those, yet, several of the most significantly
changing metabolites with very high intensity were not precisely
annotated. These molecules included three closely eluting peaks
(m/z 331.08, 329.06, 299.05) (Figure 3), possibly flavonoid
structures, as the survey for potential molecular formulae pointed
solely to flavonoids, mainly flavonols and flavanols, and their UV
spectra resembled a typical flavanol absorbance. The flavonoids of
rye bran in general are not studied and reported in detail, and thus
the structural identity of these metabolites will be analyzed in a
future study.
A particularly interesting group of unknown peaks possibly
containing nitrogen and most likely represent related metabolites
was observed in the analysis (m/z 532.14, 548.14, 502.13, 518.13)
(Figure 3). These compounds eluted in the same region and their
molecular formulae referred to the same class of indole containing
compounds. All of these were found only in the extractable
fraction (both E and EL), and were rapidly degraded in both
samples in the incubation. Similarly, also various smaller nitrogen
containing metabolites accumulated as end products (m/z 150.05,
190.05, 234.11) (Figure 3). Those resemble metabolites that have
been detected in human plasma as microbial conversion process of
dietary tryptophan [19]. In the case of the rye fractions, these
metabolites could not be identified based on MS spectral
properties, but will be addressed with targeted approach has been
used for the structural resolving of phytochemicals [37].
The last few minutes in the chromatographic separation eluted
hydrophobic metabolites such as lipids. In the rye bran fractions
this region was relatively rich in metabolites, and also here
different accumulation patterns were observed for individual peaks
(m/z 329.23, 357.26, 229.24, 373.26), suggesting modification by
the colonic microbiota. Although the metabolites in this region
were not identified one by one, the characteristic increase of 2 amu
in the molecular ion reflects to the reduction of carbon-carbon
double bonds that is generally performed by microbiota on e.g.
polyphenols. The hydrophobic faction will be taken into further
analysis with non-polar extraction solvents and chromatographic
conditions (lipidomics).
Figure 3. Identified and some of the most significantly changing unidentified metabolite markers sorted on heat map. The
hierarchical clustering is performed with Pearson correlation. The different sample types are depicted as follows: E, extractable fraction; EL,
extractable fraction in low concentration; UE, unextractable fraction; FB, fecal background followed by the sampling time (0, 4, 12, 48 h) and replicate
number (1, 2, 3).
doi:10.1371/journal.pone.0039322.g003
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Nutritional Research
Colon with its microbiota functions as a bioreactor with
metabolic capacity far beyond that of the human metabolism.
Large metabolome-level analyses on the effect of microbiota on
the dietary phytochemicals are scarce, as most of the studies have
focused on the detailed analysis of single or few compounds.
However, the large-scale in vitro studies from whole food items
provide important addition when the fate of dietary phytochem-
icals is examined, as they allow distinguishing between metabolites
originating from microbial conversion from the ones produced by
host metabolism [38]. The information of microbial metabolic
conversions on dietary phytochemicals is especially valuable, when
it is connected with nutritional post-prandial or intervention
studies. When unknown molecules from similar non-targeted
profiling arrays appear from human derived samples, the analysis
of microbiota treated samples (from the same or similar dietary
item or raw material) will help identification of the in vivo
metabolites, and allow distinguishing whether they are native plant
made metabolites or microbial conversion products. The simple
metabolite extraction and the same analytical conditions hold true
for all sample types in the non-targeted metabolomics assay,
enabling effective parallel profiling. Similarly, multi-level non-
targeted profiling can be applied on raw material, on processed
foods, and also mammalian samples (biofluids from humans,
tissues from animal feeding trials), as well as on temporal sample
set providing straightforward approach for nutrikinetics studies.
For example in our approach, we could show that the
benzoxazinoid metabolites are processed by microbiota – firstly
released from the sugar and also seemingly undergo modifications
on the aglycon part as well. The fact that we had recently analysed
the benzoxazinoids from the starting material (the rye bran) with
the very same analytical approach enabled easy identification of
those metabolites. Furthermore, these observations raise a totally
new branch of research – targeted analysis of the benzoxazinoid
metabolism as dietary metabolite family.
The metabolomics analyses on the effect of microbiota have
mainly been done in human or animal models, with the NMR
profiling experiments dominating the field [39]). Although NMR
gives a relatively broad, quantitative profile of e.g. main blood
metabolites, it fails in detecting low concentration molecules. LC-
MS based analytics offer more sensitive approach to monitor also
the diet derived phytochemicals, many of which are found in
circulation in low levels, but yet may exert important bioactive
capacity that needs to be taken into account when the effect of diet
on health is addressed. The major bottleneck limitation of large-
scale LC-MS profiling studies is the lack of tools for clear cut
identification of the measured metabolite signals. Compound
collections with MS spectral information such as human
metabolome database [40] are gradually gathering up information
mainly on endogenous human metabolites, easing the interpreta-
tion of human plasma and urine derived MS-data. However, the
metabolites harboring our body via food, especially plant-based
products, multiply the number of metabolites present endoge-
nously by several factors. As the majority of phytochemicals
Figure 4. Occurrence of the identified lignan metabolites in the
analysis. Three replicates from each sample type are shown; the
symbols are: squares, extractable fraction (E); circles, extractable fraction
in lower concentration (EL); triangles, unextractable fraction (UE); and
crosses, faecal background (FB) samples. The different time points are
represented with different colors: red, 0 h; green, 4 h; turquoise, 12 h;
and blue, 48 h.
doi:10.1371/journal.pone.0039322.g004
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detection of unknown metabolites in any wide scale MS analysis
is foreseen still for quite some while. On the other hand, the utility
of non-targeted LC-MS profiling in bringing out previously non-
characterized metabolic components is outweighing, as it takes
into account all the chemical information in the taken sample, in
contrary to targeted measurements that overlook any other
compounds than the focused ones.
In our study, the number of compounds detected in the rye bran
fractions was very large, and further increased by the bacterial
transformations, resulting in an overwhelming myriad of chemi-
cals, (that, theoretically, could be bioavailabe and enter circula-
tion). Even many of the metabolites present in most abundant
signals were previously non-characterized in the source material
(rye bran), which underlines the importance of non-targeted
profiling arrays in bringing out novel chemical information. Our
analysis showed the importance of colonic conversions in
modulating the diet derived chemical species, and demonstrates
the applicability of MS profiling for large scale metabolite
screening analyses as first step in analysing dietary phytochemical
composition, which is pre-requisite for the investigation of the
relationship between diet and human health status.
Materials and Methods
Ethics Statement
At the time of the performance of the presented colon model
experiment, the Ethical Committee of VTT Technical Research
Centre of Finland was not involved, because the research do not
fill the criteria of medical research and donation of feces was a
non-invasive method and results were not obtained on personal-
ized level. Volunteered donors of the inoculum were informed
orally and the origins of the faecal samples were shielded by
number coding and key was known only by one technician and
responsible scientist (Aura). All results were expressed per pooled
faecal inoculum with no direct reference to a particular person.
The voluntary donors of the faeces belong to a panel and have
given their consent orally before 2010, received oral and written
information on the studies regularly and have a possibility to refuse
anytime from participation. Ethical Committee of VTT Technical
Research Centre of Finland confirmed in their statement in 2010
that no permission is needed according to the applicable law,
however, a written consent was recommended and applied instead
of oral change of information and consent. After obtaining the
statement and guidelines from Ethical Committee of VTT in
2010, all donors of the panel have signed an informed consent and
the same principals as above are approved and confirmed as
adequate measures as far as the ethics are concerned.
The VTT colon models have been applied in several projects,
which were audited by institutional quality and safety authorities,
the Safety-quality panel and biological hazard authorities of VTT.
Faeces from health volunteers are not classified in the worst hazard
level in terms of pathogenic bacteria and all personnel working
with feaces have been vaccinated against polio, tetanus and
hepatitis A and B. All possible laboratory ware is disposable.
Desinfectant effective also on viruses (Virkon) is used for non-
disposable ware and instructed laboratory personnel take care of
the wastes.
In Vitro Fermentation of Rye Bran
The extractable fraction was released from the rye matrix in the
enzymatic hydrolysis of the extruded rye bran, and the soluble
clear supernatant was bound to the column, eluted, dried and
applied in the model in two concentrations. The unextractable
residue is the core rye matrix resistant to the hydrolysis, but
degradable by the microbiota releasing the phytochemicals for
further conversions.
Bran samples of rye (Secale cereale) from Finnish origin were used
for the study. The extractable fraction was released from the rye
matrix in the enzymatic hydrolysis of the extruded rye bran and
separated from the core unextractable rye matrix resistant to the
hydrolysis. The soluble fraction was further purified chromato-
graphically and dried to a phenolic-rich powder [41]. Both
fractions were introduced to the colon model as described
previously [42] in two experiments with following modifications:
Fecal material was collected from four donors (enhances the
diversity of the microbiota and evens up the differences in the
conversion activities of the microbial populations), who had not
received antibiotics for at least 5 months, and had not eaten
flaxseed, rye or berries for at least 3–4 days before donation.
Freshly passed feces was immediately transferred to a strictly
anaerobic chamber for further processing of the fecal suspension
16.7% (w/v) by homogenizing the feces in 0.22 M carbonate
20.02 M phosphate buffer [43].
The water-extractable, soluble fraction of the phytochemicals
was used in two different concentrations, 1 g per 10 ml of
inoculum, termed as extractable fraction (E) and 0.25 g per 10 ml
of the inoculum, termed as extractable sample in lower
concentration (EL), at initial pH values of 7.1460.02 and
7.6360.03, respectively. The lower dose was tested, because our
earlier analyses showed that some of the phytochemical conver-
sions can be suppressed when high dose of the polyphenolic
mixture was applied [23]. The residual fraction was applied in one
concentration (1 g/10 ml) and was termed as unextractable
fraction (UE). Additionally, the metabolomics analysis was
performed on the faecal background samples (FB) without addition
of rye bran extracts, to be able to identify the metabolites
originating from the diet of the donors of the faecal inoculum.
Figure 5. Occurrence of the benzoxazinoid HBOA-hexose and its deglucosylated form. Three replicates from each sample type are shown;
the symbols are: squares, extractable fraction (E); circles, extractable fraction in lower concentration (EL); triangles, unextractable fraction (UE); and
crosses, faecal background (FB) samples. The different time points are represented with different colors: red, 0 h; green, 4 h; turquoise, 12 h; and
blue, 48 h.
doi:10.1371/journal.pone.0039322.g005
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The bacterial cells were removed from the samples as follows:
100 mg of freeze-dried in vitro fermentation samples were
suspended in saline (0.9% NaCl) in a ratio 9 ml of saline per mg
sample in triplicates. The suspension was centrifuged (2500 rpm
10 min) and a 1.5 ml aliquot of the supernatant was moved to
eppendorf tube and centrifuged once more (14 000 rpm 10 min).
500 ml of the supernatant was filtered (PTFE 0.4 mm), extracted
with equal amount of ethyl acetate, evaporated to dryness under
nitrogen flow, and stored in 220uC. Upon UPLC-qTOF-MS
analysis the samples were redissolved in 200 ml of 75% MeOH
+0.1% Formic acid and filtered (PTFE 0.2 mm), and 4 mlo f
sample was injected.
UPLC-qTOF-MS Analysis
Metabolite analysis was carried out using a UPLC-qTOF-MS
system (Waters Acquity UPLC and Synapt HDMS in the standard
qTOF mode). The column was a 10062.1 mm i.d., 1.7 mm UPLC
BEH C18 column (Waters Acquity). The mobile phase consisted
of 0.1% formic acid in acetonitrile: water (5:95, v/v) (phase A), and
0.1% formic acid in acetonitrile (phase B) in a linear gradient:
100–72% A over 22 min, 72–60% A over 0.5 min, 60–0% A over
0.5 min, held at 100% B for a further 1.5 min, then returned to
the initial conditions (100% A) in 0.5 min, and conditioning at
100% A. The flow rate was 0.3 ml/min; column temperature was
kept at 35uC. Ionization was performed with electrospray
ionization (ESI) in the positive and negative modes. The following
settings were applied during the LC–MS runs: capillary voltage at
3.0 kV; cone voltage at 30 eV; collision energy at 3 eV and at
20 eV; argon was used as collision gas. For the LC–MS/MS
analysis 20 and 35 eV collision was used. The m/z range was 50–
1500 Da. The MS was calibrated using sodium formate, and
leucine enkephalin was used as the lock mass. The MassLynx
software version 4.1 (Waters) was used to control all instruments
and calculate the accurate masses.
A standard mixture was used to monitor the quality of the
chromatogramandreproducibilityoftheretentiontimethroughout
the runs and to aid in metabolite identification, and contained
40 mg/ml of each of the following compounds: L-tryptophan, L-
phenylalanine, p-coumaric acid, caffeic acid, sinapic acid, benzoic
acid, quercetin dehydrate, kaempferol, rutin, and trans-resveratrol
(all purchased from Sigma); naringenin, chlorogenic acid hemihy-
drate, trans-cinnamic acid and isorhamnetin (Fluka), ferulic acid
(Aldrich) and tomatine (Apin chemicals). Additional standard
mixture of small phenolic metabolites and lignans was included in
the LC-MS analysis which contained secoisolariciresinol, laricir-
esinol,pinoresinol,andmatairesinol(Arbonova,Turku,Finland);p-
hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, vanillic acid, 3-
phenylpropionic acid, and (S)-3-hydroxy-3-phenylpropionic acid
(Sigma).
Data Analysis
The chromatograms obtained from UPLC-qTOF-MS analysis
were processed by the MarkerLynx 4.1 software (Waters) for mass
signal extraction and alignment. To remove false zero values from
the data matrix following rules based on signals of replicate
measurement were applied: [1] if metabolite values are zero in
more than 50% of the replicates and the non-zero values are
smaller than the threshold (default intensity =5), then zero is
considered a true zero and replicate values are replaced with zeros;
[2] if metabolite values are zero in more than 50% of the replicates
and the non-zero values are higher than the threshold (default
intensity =5), then zero is considered false and is replaced with a
‘‘missing value’’; [3] if metabolite signals of zero are present in less
than 50% of the replicates, then zero is considered false and
replaced with the average value of non-zero reference values.
Next, data matrix was reduced by removing the very low-intensity
metabolite values, which are not amenable for identification in
non-targeted profiling assay. This was done by omitting markers
that had maximum intensity values lower than 10, resulting in data
set of 2147 metabolite signals for further analysis. Data handling
was carried out by MATLAB and PLS_Toolbox (version 5,
Eigenvector Inc. Seattle, WA) for unscaled data.
Principal component analysis (PCA) was applied for visualiza-
tion of the pattern of different treatments and to recognize the
most important markers signaling the differences between time
points [24]. PCA decomposes the original data into a set of new
(latent) variables (utilizing the common variances in the data) that
are linear combinations of the original variables, also called
Principal Components – PCs –. These new variables, PCs, exhibit
two different characteristics: scores, that depicts the position of
objects (treatments) in the new variable space; and loadings, that
are weighted positions of original variables (markers) in the new
variable space. Thus by exploring scores object patterns in the
data and trends can be studied (how objects are; similar or
different) whereas exploring loadings the variables accounting for
those trends can be spotted (why objects are similar or different).
K-means cluster analysis and hierarchical clustering were
performed by the open-source software Multi experiment Viewer
(MeV, http://www.tm4.org/ [44]). These were applied to
visualize the common trends in the temporal profile of the
different metabolite markers (K-means clustering) as well as
visualizing the abundance of the markers when compared against
the other markers present in the same cluster. The number of
clusters was set to nine.
The identification of metabolites was performed as described
previously [45]. In short, if commercial standards were included in
the analysis, the retention time and MS/MS fragmentation were
used as basis for identification. For other metabolites, the accurate
mass and molecular formula predictions were screened of putative
molecules from the Dictionary of Natural Products (Chapman &
Hall/CRC), SciFinder Scholar database (SciFinder ScholarTM
2007), and ChemSpider chemical database (http://www.
chemspider.com/). The MS/MS fragmentation of the metabolites
was compared with candidate molecules found in databases, and
verified with earlier literature on same or similar compounds.
Supporting Information
Figure S1 The base peak ion chromatogram of extract-
able fraction in ESI(-) MS after 0, 4, 12, and 48 hours
incubation.
(TIF)
Figure S2 The base peak ion chromatogram of extract-
able fraction with low concentration in ESI(-) MS after 0,
4, 12, and 48 hours incubation.
(TIF)
Figure S3 The base peak ion chromatogram of unex-
tractable fraction in ESI(-) MS after 0, 4, 12, and 48
hours incubation.
(TIF)
Figure S4 The base peak ion chromatogram of faecal
background in ESI(-) MS after 0, 4, 12, and 48 hours
incubation.
(TIF)
Figure S5 Number of metabolite markers, and the
proportion of significantly changing markers found in
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39322each sample type. (A) The number of metabolite markers in
each of the samples types after the data cleaning process, and
number of significantly decreasing and increasing markers in each
sample type. Marker was considered to be significantly changed if
the value between two time points had fold change either ,0.5 or
.2, with p-value less than 0.05. (B) The distribution of the
increasing (upper pie charts) and decreasing (lower pie charts)
markers in the incubation after 4, 12, and 48 hours. Some of the
markers were intermediate metabolites that were first increasing,
but towards the end of the incubation were again decreasing, and
these are shown on purple sectors in the upper pie charts.
(TIF)
Table S1 MS/MS fragmentation of the key metabolites.
Identification was done based on comparison with standards, or
with earlier reported MS/MS results.
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